Stocktoria
IDEXX LABORATORIES INC /DE IDXX
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1991-06-21
IDEXX LABORATORIES INC /DE financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.3B | $3.9B | $3.7B | $3.4B | $3.2B |
| Gross profit | $2.7B | $2.4B | $2.2B | $2.0B | $1.9B |
| R&D expense | $251.2M | $219.8M | $191.0M | $254.8M | $161.0M |
| Operating income | $1.4B | $1.1B | $1.1B | $898.8M | $932.0M |
| Interest expense | — | — | $41.6M | $39.9M | $29.8M |
| Income tax | $264.7M | $222.0M | $216.1M | $180.9M | $157.8M |
| Net income | $1.1B | $887.9M | $845.0M | $679.1M | $744.8M |
| EPS (diluted) | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 |
| Operating cash flow | $1.2B | $929.0M | $906.5M | $543.0M | $755.5M |
| Free cash flow | $1.1B | $808.1M | $772.9M | $394.1M | $636.0M |
| Cash & equivalents | $180.1M | $288.3M | $453.9M | $112.5M | $144.5M |
| Inventory | $377.8M | $381.9M | $380.3M | $367.8M | $269.0M |
| Total assets | $3.4B | $3.3B | $3.3B | $2.7B | $2.4B |
| Total liabilities | $1.7B | $1.7B | $1.8B | $2.1B | $1.7B |
| Shareholders' equity | $1.6B | $1.6B | $1.5B | $608.7M | $690.0M |
Source: SEC EDGAR filings · CIK 0000874716 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.